Unraveling the debate: Can the skin manifestations of SARS-CoV-2 infection and vaccination be explained by the reactivation of herpes virus?
COVID-19
Sars-CoV-2
adverse effects
herpes simplex
herpes zoster
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
31
08
2023
received:
19
07
2023
accepted:
14
09
2023
medline:
4
12
2023
pubmed:
13
10
2023
entrez:
13
10
2023
Statut:
ppublish
Résumé
Since the COVID-19 outbreak, there have been numerous reports concerning COVID-19 skin manifestations. Debate has ensued as to whether these lesions are unique or represent a form of viral reactivation. The aim of this research was to compare the incidence of herpetic skin lesions between a COVID-19 group, a Sars-CoV-2 mRNA vaccination group, and their respective controls, taking into account their Herpesviridae carrier status. To achieve this goal, the Maccabi Healthcare Services' database was scanned and cohorts of both verified COVID-19 and mRNA vaccinated patients were extracted and matched to random control groups. Patients with a documented occurrence of any Herpesviridae infection that occurred prior to the studied 'event' (i.e., COVID-19 or mRNA vaccination) were regarded as carriers of Herpesviridae. A COVID-19-related or vaccination-related lesion was defined as a clinically diagnosed herpetic lesion appearing 1 month after the index date. In the COVID-19 cohort, there was an insignificant difference in herpetic lesion incidence between the groups. However, logistic regression demonstrated that the interaction of COVID-19 with the Herpesviridae carrier status was statistically significant. For the vaccination cohort, the data showed statistically significant differences between groups in herpetic frequencies, which manifested as an almost 2-fold odds of developing a herpetic lesion. In conclusion, following the analysis of two large cohorts, there is evidence to support the contribution of both COVID-19 and the mRNA vaccine to the reactivation of Herpesviridae. Our results diminish the idea that COVID-19 has unique, herpetic-like lesions.
Identifiants
pubmed: 37830227
doi: 10.1111/1346-8138.16984
doi:
Substances chimiques
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1594-1602Subventions
Organisme : KSM (Kahn-Sagol-Maccabi) Research and Innovation
Informations de copyright
© 2023 Japanese Dermatological Association.
Références
Ferreira ACA, Romão TT, Macedo YS, Pupe C, Nascimento OJM. COVID-19 and herpes zoster co-infection presenting with trigeminal neuropathy. Eur J Neurol. 2020;27:1748-1750.
Xu R, Zhou Y, Cai L, Wang L, Han J, Yang X, et al. Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19. Br J Dermatol. 2020;183:1145-1147.
Maia CMF, Marques NP, de Lucena EHG, de Rezende LF, Martelli DRB, Martelli-Júnior H. Increase in the number of herpes zoster cases in Brazil related to the COVID-19 pandemic. Int J Infect Dis. 2021;1:732-733.
Marzano AV, Genovese G, Fabbrocini G, Pigatto P, Monfrecola G, Piraccini BM, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol. 2020;83:280-285.
Mahé A, Birckel E, Merklen C, Lefèbvre P, Hannedouche C, Jost M, et al. Histology of skin lesions establishes that the vesicular rash associated with COVID-19 is not ‘varicella-like. J Eur Acad Dermatol Venereol. 2020;34:e559-e561.
Llamas-Velasco M, Rodríguez-Jiménez P, Chicharro P, De Argila D, Muñoz-Hernández P, Daudén E. Reply to “Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients”: to consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out. J Am Acad Dermatol. 2020;83:e253-e254.
Marzano AV, Genovese G. Response to: Reply to ‘Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients’: To consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out. J Am Acad Dermatol. 2020;83:e255-e256.
Fernandez-Nieto D, Ortega-Quijano D, Jimenez-Cauhe J, Burgos-Blasco P, de Perosanz-Lobo D, Suarez-Valle A, et al. Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital. Clin Exp Dermatol. 2020;45:872-875.
Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183:71-77.
Lim SYD, Tey HL. Response to ‘classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases’: vesicular eruption in COVID-19 - to exclude varicella. Br J Dermatol. 2020;183:790-791.
Genovese G, Moltrasio C, Berti E, Marzano AV. Skin manifestations associated with COVID-19: current knowledge and future perspectives. Dermatology. 2021;237:1-12.
Marzano AV, Cassano N, Genovese G, Moltrasio C, Vena GA. Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue. Br J Dermatol. 2020;183:431-442.
Tan SW, Tam YC, Oh CC. Skin manifestations of COVID-19: a worldwide review. JAAD Int. 2021;2:119-133.
Nakashima C, Kato M, Otsuka A. Cutaneous manifestations of COVID-19 and COVID-19 vaccination. J Dermatol. 2023;50:280-289.
Martinez-Reviejo R, Tejada S, Adebanjo GAR, Chello C, Machado MC, Parisella FR, et al. Varicella-zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: new insights. Eur J Intern Med. 2022;104:73-79.
Katz J, Yue S, Xue W. Herpes simplex and herpes zoster viruses in COVID-19 patients. Ir J Med Sci. 2022;191:1093-1097.
CDC. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. 2023. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html
Opstelten W, Van Loon AM, Schuller M, Van Wijck AJM, Van Essen GA, Moons KGM, et al. Clinical diagnosis of herpes zoster in family practice. Ann Fam Med. 2007;5:305.
Huang J, Wu Y, Wang M, Jiang J, Zhu Y, Kumar R, et al. The global disease burden of varicella-zoster virus infection from 1990 to 2019. J Med Virol. 2022;94:2736-2746.
James C, Harfouche M, Welton NJ, Turner KME, Abu-Raddad LJ, Gottlieb SL, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020;98:315-329.
Thomas LE, Yang S, Wojdyla D, Schaubel DE. Matching with time-dependent treatments: a review and look forward. Stat Med. 2020;39:2350.
Thiese MS, Ronna B, Ott U. P value interpretations and considerations. J Thorac Dis. 2016;8:E928.
Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a Nationwide setting. N Engl J Med. 2021;385:1078-1090.
Thada PK, Ata F, Ali M, Affas MN, Bhandari J, Sarwar S, et al. Clinical characteristics and outcomes of patients with herpes zoster infection in the context of SARS-CoV-2 infection. A case report and a systematic review. Qatar Med J. 2022;2022:41.